Position in ADMA
as of Jun 30, 2026
· filed Jul 13, 2026
Position Value
$5,022,000
+$1,192,750 QoQ
Shares Held
600,000
+41.2% QoQ
Ownership
0.259%
of shares outstanding
% of Portfolio
0.56%
of 13F equity value
Holder Rank
#1
of 18 holders
Holding Since
Mar 2020
8 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in ADMA Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026ARDSLEY ADVISORY PARTNERS LP holds $24,823,800 across 5 Biotechnology names. ADMA ranks #3 (20.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
15,000 | $7,450,950 | |
| 2 | JAZZ |
Jazz Pharmaceuticals plc
|
30,000 | $7,229,100 | |
| 3 | ADMA |
Adma Biologics, Inc.
This page
|
600,000 | $5,022,000 | |
| 4 | FTRE |
Fortrea Holdings Inc.
|
175,000 | $3,045,000 | |
| 5 | ALDX |
Aldeyra Therapeutics, Inc.
|
975,000 | $2,076,750 |
All Filings in ADMA
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $5,022,000 | 600,000 | Shares | Sole | 2026-07-13 | |
| 2026-03-31 | $3,829,250 | 425,000 | Shares | Sole | 2026-05-15 | |
| 2025-09-30 | $6,230,500 | 425,000 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $7,284,000 | 400,000 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $5,952,000 | 300,000 | Shares | Sole | 2025-05-15 | |
| 2020-09-30 | $224,899 | 94,100 | Shares | Sole | 2020-11-13 | |
| 2020-06-30 | $284,503 | 97,100 | Shares | Sole | 2020-08-14 | |
| 2020-03-31 | $214,848 | 74,600 | Shares | Sole | 2020-05-15 | |
| No filing history on record for this holder in this stock. | ||||||